Navigation Links
Study Finds Less Toxic Treatment for Myeloma
Date:10/22/2009

Lower dose of standard medication leads to better outcome, researchers say

THURSDAY, Oct. 22 (HealthDay News) -- Cancer researchers say they have a better treatment for patients with newly diagnosed multiple myeloma than the current standard therapy.

Their study finds that treatment with lenalidomide plus low-dose dexamethasone is associated with better short-term survival and with lower toxicity than lenalidomide plus high-dose dexamethasone, which is the mainstay of therapy for the bone marrow cancer.

The study included more than 400 patients with untreated, symptomatic myeloma who received lenalidomide (25 milligrams for 21 days) plus a high dose of dexamethasone (40 milligrams on days one to four, nine to 12, and 17 to 20 of a 28-day cycle), or who received lenalidomide on the same schedule with a low dose of dexamethasone (40 milligrams on days one, eight, 15 and 22 of a 28-day cycle).

Within four cycles, 79 percent of patients in the high-dose group and 68 percent of patients in the low-dose group had complete or partial response, the researchers found. After one year, overall survival was 96 percent in the low-dose group and 87 percent in the high-dose group. These findings led the researchers to stop the trial and switch patients in the high-dose group to low-dose therapy.

During the first four months of the study, 52 percent of patients in the high-dose group and 35 percent of those in the low-dose group had grade 3 or worse toxic effects. These included deep-vein thrombosis, fatigue and infections, including pneumonia.

Also during the first four months of the trial, 5 percent of patients in the high-dose group died, compared with less than 1 percent of those in the low-dose group, the study authors reported.

"High-dose dexamethasone in a community setting seems more toxic than low-dose dexamethasone, with more early deaths in the first four months, increased risk of thromboembolic complications, and higher overall risk of serious adverse events, particularly in patients older than 65 years," wrote Dr. S. Vincent Rajkumar, of the Mayo Clinic, and colleagues.

The authors concluded that the trial "shows that low-dose dexamethasone in conjunction with lenalidomide is an active regimen for newly diagnosed myeloma with acceptable toxicity and low early mortality."

They also noted that "the use of high-dose dexamethasone is not needed for the most part in the context of new active agents for myeloma, and as a result almost all current phase 3 trials have adopted low-dose dexamethasone as the standard in combination regimens."

The study was published online Oct. 21 in The Lancet Oncology.

More information

The American Cancer Society has more about multiple myeloma.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Oct. 21, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... A recent ... continue to face challenges in getting employees to understand and use the free preventive ... of the nation’s leading non-profit business groups of large, self-insured public and private employers, ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... has found that more than 40 percent of participating fifth-grade students already have ... of Allergy and Asthma Clinical Research in the Division of Pulmonary, Allergy and ...
(Date:5/5/2016)... ... 2016 , ... Sun Health registered nurse Brittany Eads and ... Care Transitions program at the 9th Annual Orthopedic and Spine Summit held ... Post-Acute Environment Through Effective Transitions of Care.” , Major changes are taking place ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs (TTL) is ... eve of National Nurses Week (May 6-12). Currently, HireNurses is a job ... enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Lung Institute will celebrate its three-year anniversary on ... most clinic locations throughout the month of May. To date, the Lung Institute has treated ... that we’ve seen is a testament to the success of this treatment and to the ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)... Ore. , May 3, 2016   BIOTRONIK ... importance of extending care beyond the implant at the ... May 4-7 in San Francisco . ... continually delivering the highest quality of patient care and ... are cared for each and every tomorrow," said ...
Breaking Medicine Technology: